Lavipharm S.A. (ATSE: LAVI)
Health Care · Pharmaceuticals · GR
€1.51
-3.70% today · +86.4% 1Y
Lavipharm S.A. (ATSE: LAVI) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $288.74M and employs 306 people.
Over the last twelve months the share price has gained 86.4%, trading between 0.76 and 1.74.
Tweenvest scores Lavipharm S.A. across four factors: quality 69/100, value 37/100, growth 54/100, dividend 47/100. Its strongest factor is quality.
LAVI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $288.74M
- Revenue (TTM)
- $80.33M
- P/E
- 45.98
- EPS
- 0.03
- Dividend yield
- 1.32%
- Beta (5Y)
- 1.01
- 52-week high
- €1.74
- 52-week low
- €0.76
- Avg volume (3M)
- —
- Shares outstanding
- 170.78M
- Employees
- 306
- Next earnings
- —
About Lavipharm S.A.
Lavipharm S.A. is a company that specializes in the comprehensive lifecycle of pharmaceutical, dermocosmetic, and general healthcare products, from initial research and development to manufacturing, importation, marketing, and distribution. Its operations span both the Greek domestic market and international territories. The company's diverse pharmaceutical offerings cater to numerous therapeutic areas, including cardiology, chronic pain management, oncology, central nervous system disorders, general medicine, gastrointestinal health, and urology. In addition to prescription medications, Lavipharm provides a range of over-the-counter (OTC) drugs such as antiseptics, analgesics, and anti-lice treatments, alongside various skincare solutions. This enterprise, headquartered in Paiania, Greece, was established in 1911.
- ISIN
- GRS246003008
- Founded
- 1911
- Listed since
- Nov 8, 1995
- Exchange
- The Athens Stock Exchange
- Currency
- EUR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Aurora Cannabis Inc.TSX: ACB | $295.82M | CA$6.42 | +1.58% |
| Fuji Pharma Co., Ltd.TSE: 4554 | $293.63M | ¥1,780.00 | +3.49% |
| EyePoint, Inc.NasdaqGM: EYPT | $293.12M | $3.50 | +2.94% |
| BioAge Labs, Inc.NasdaqGS: BIOA | $290.99M | $6.34 | +2.09% |
| Fulcrum Therapeutics, Inc.NasdaqGM: FULC | $287.64M | $3.83 | +1.59% |
| Hua Medicine (Shanghai) Ltd.SEHK: 2552 | $283.77M | HK$2.23 | -4.90% |
| Tiansheng Pharmaceutical Group Co., Ltd.SZSE: 002872 | $283.43M | CN¥5.97 | -3.55% |
| Starpharma Holdings LimitedASX: SPL | $282.89M | AU$0.85 | +5.62% |
Figures last refreshed Oct 11, 2026.